Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

NORCROSS, Ga., March 29, 2013 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the full year and fourth quarter, ended December 31, 2012. These results are included in the Company's Quarterly Report on Form 10-K, which has been filed with the SEC.

"It was a year of great progress for our Company," said Peter G. Traber , M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics. "We completed a significant fundraising and our stock was listed on the NASDAQ Capital Market earlier in the year, we relocated our headquarters to Norcross, Georgia during the fourth quarter, and we made significant advances developing our fibrosis program. We have continued this progress into 2013, having submitted an IND for GR-MD-02 in January and received the FDA's ok that we could proceed with a Phase 1 clinical trial. We expect to initiate a Phase 1 clinical trial of GR-MD-02 during the second quarter of 2013 in patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis and have engaged CTI Clinical Trial Services to provide services related to this trial. The novel mechanism of action of GR-MD-02, in combination with compelling preclinical data, gives us great hope that this compound may ultimately meet the needs of patients with this deadly disease that currently has no approved therapeutic options."

At December 31, 2012, the Company had $9.4 million of non-restricted cash and cash equivalents available to fund future operations.  The Company believes that with the funds on hand at December 31, 2012, there is sufficient cash to fund core operations and planned research and development through the first quarter of 2014.

For the fourth quarter of 2012, the Company reported a net lo
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... og SHENZHEN , Kina, ... Co., LTD, (BGI Tech), et datterselskab af BGI, ... en ny human whole exome-sekvenseringstjeneste baseret på Complete ... højt anset i branchen for at levere patenterede ... af alle typer varianter, blev købt af BGI ...
(Date:7/22/2014)... , July 22, 2014 Hussey Copper ... MD-Cu 29 antimicrobial copper announces Pullman Regional Hospital,s ... first EPA-registered antimicrobial solid touch surface, at a nominal ... of MRSA, E-coli and other bacteria within 2 hours of ... protecting against bacteria and infectious diseases in its facilities. ...
(Date:7/22/2014)... Quorum Review IRB, the industry leader in central ... called Quick Step™ . The offering went live on ... industry’s need for seamless study start-up with a large volume ... planning 50 or more North American investigator sites, as well ... count of 80 or more. Qualifying studies may also enroll ...
(Date:7/22/2014)... Biofeedback – When a behavioral problem ... medication to best treat it can become a matter ... electroencephalography (EEG) can help predict which medicine will offer ... adverse drug events. , The article “Medication Prediction ... issue of the journal Biofeedback offers evidence that quantitative ...
Breaking Biology Technology:BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 3
... , SHANDONG , ... YCT,International Group, Inc. ("China YCT" or the "Company") (OTC Bulletin ... the State Intellectual,Property Office of the People,s Republic of ... Spring Pharmaceutical Co.,Ltd., for "a unique method of making ginkgo ...
... soon be sporting RFID tags to improve their safety. ... Ontario Centres of Excellence (OCE) are undertaking a $1.4 ... can be used to notify subway vehicles of the ... "Our customers have asked us if we could ...
... ... University,s R&D Facility , ... Boston, MA (Vocus) January 21, 2010 -- The University of Massachusetts Boston today ... sample preparation instruments, has moved its research and development operations to the university,s ...
Cached Biology Technology:China YCT International Group, Inc. Announces That the State Intellectual Property Office of the People's Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd. 2China YCT International Group, Inc. Announces That the State Intellectual Property Office of the People's Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd. 3RFID tags to boost transit worker safety 2UMass Boston's Venture Development Center Announces New Bio-Science Partner 2UMass Boston's Venture Development Center Announces New Bio-Science Partner 3
(Date:7/22/2014)... genus of planthopper known as Conosimus, which now includes ... in the southern part of the Iberian Peninsula in ... appears in the open-access Journal of Insect Science ... Conosimus baenai , has been named after Manuel ... taxonomy of Iberian Hemiptera. , Conosimus baenai ...
(Date:7/21/2014)... Jocelyn Millar , a professor of entomology ... of Chemistry at the University of California, Riverside, ... by the International Society of Chemical Ecology ( ISCE ... Silver Medal is the society,s highest honor. It ... contributions to chemical ecology, the study of chemicals that ...
(Date:7/21/2014)... tracking to monitor seals, every movement, researchers have shown ... drawn to offshore wind farms and pipelines. Those man-made ... grounds, according to a study published in the Cell ... , "I was shocked when I first saw ... Sheringham Shoal," an offshore wind farm in the United ...
Breaking Biology News(10 mins):UC Riverside entomologist receives international honor for chemical ecology contributions 2Seals forage at offshore wind farms 2
... years of research over five degraded landscapes in the National Park ... that field mice base their diet on holm oak and pine ... scrubland in the forests. The trees in the ... predators which are impeding their expansion over the mountains. In 98.5% ...
... A University of Leicester-led study may have uncovered the ... older people with high blood pressure, when compared to other ... by Bryan Williams, Professor of Medicine at the University of ... in the prestigious Journal of the American College of ...
... A new policy paper by Rice University,s Baker ... the size and influence of noncommercial traders, or "speculators," ... by the Commodities Futures Modernization Act of 2000. Speculators ... positions in the U.S. oil futures market, compared with ...
Cached Biology News:Small rodents encourage the formation of scrubland in Spain 2Beta-blockers and stroke -- new insights into their use for older people 2Study: Oil speculators dominate open interest in oil futures 2Study: Oil speculators dominate open interest in oil futures 3
The product contains 2 ml Dynabeads® Epoxy (4.5 μm). Supplied at 4 x 10e8 beads/ml...
... to Endothelin B Receptor Like Protein ... Protein 2 (ETBR-LP-2) has been reported ... isolated from human brain and colon ... peptide (unfortunately, the amino acid sequence ...
... recognized by A300-183A maps to ... of human quaking homolog according ... The epitope is not ... 3, 4, 6, 7 or ...
Flotillin-2 (ESA) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 29, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Biology Products: